molecules of the month


oral sel. IDO1 dioxygenase inhibitor

100 mg QD, in I/O combo studies for cancer

acts on apo-IDO1 displacing heme co-factor

Mol. Cancer Ther., Dec. 9, 2020

BMS, Princeton, NJ / Flexus, San Carlos, CA

Chemical structure of molecule linrodostat inhibitor
1 min read

Bristol Myers Squibb (BMS) oral selective heme-displacing IDO1 inhibitor

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: